You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RET fusion lung cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Nonsmall Cell Lung Cancer Trial in Shanghai (HS-10365 capsules)

Recruiting
  • Nonsmall Cell Lung Cancer
  • HS-10365 capsules
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Nov 22, 2023

NSCLC Trial in Shanghai (SY-5007)

Recruiting
  • Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Sep 4, 2023

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Chang chun

Not yet recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +3 more
  • Chang chun, Jilin, China
    Jinlin Province Cancer Hosipital
Dec 21, 2022

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion

Recruiting
  • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Mar 1, 2022

    NSCLC, Thyroid Tumors Trial (LOXO-260)

    Temporarily not available
    • Carcinoma, Non-Small-Cell Lung
    • Thyroid Neoplasms
    • (no location specified)
    Sep 20, 2022

    Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Tampa

    Recruiting
    • Lung Non-Small Cell Carcinoma
    • +4 more
    • Tampa, Florida
      Moffitt Cancer Center
    Aug 16, 2022

    NSCLC Trial in Guangzhou (HA121-28 tablet)

    Recruiting
    • NSCLC
    • HA121-28 tablet
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Centre
    Aug 2, 2022

    Pralsetinib to Best Available Therapy in RET-Fusion Positive

    Enrolling by invitation
    • RET-fusion Non Small Cell Lung Cancer
    • +16 more
      • New York, New York
      • +2 more
      Aug 9, 2021

      NSCLC, Medullary Thyroid Cancer, Colon Cancer Trial in Worldwide (LOXO-292)

      Recruiting
      • Non-Small Cell Lung Cancer
      • +3 more
      • Scottsdale, Arizona
      • +84 more
      Oct 10, 2022

      Solid Tumor, Medullary Thyroid Cancer Trial in China (Selpercatinib)

      Active, not recruiting
      Has Results
      • Solid Tumor
      • Medullary Thyroid Cancer
      • Guangzhou, Guangdong, China
      • +12 more
      May 9, 2022

      RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

      Active, not recruiting
      • RET-altered Non Small Cell Lung Cancer
      • +39 more
      • pralsetinib (BLU-667)
      • Phoenix, Arizona
      • +65 more
      Nov 10, 2022

      Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer Trial in Boston (Selpercatinib, Sodium Iodine I-131, rhTSH)

      Not yet recruiting
      • Thyroid Cancer
      • +5 more
      • Boston, Massachusetts
        Massachusetts General Hospital
      Dec 20, 2022

      Non Small Cell Lung Cancer, Ovarian Cancer, RET Gene Mutation Trial in New York (RXDX-105)

      Completed
      • Non Small Cell Lung Cancer
      • +3 more
      • New York, New York
        Memorial Sloan Kettering Cancer Center 1275 York Avenue
      Sep 30, 2020

      Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation Trial in Korea, Republic of, United States (TPX-0046)

      Recruiting
      • Non Small Cell Lung Cancer
      • +4 more
      • Irvine, California
      • +15 more
      Mar 9, 2022

      NSCLC, Medullary Thyroid Cancer, Solid Tumor Trial in Shanghai, Tianjin (SY-5007)

      Recruiting
      • Non-Small Cell Lung Cancer
      • +2 more
      • Shanghai, Shanghai, China
      • +1 more
      Mar 17, 2022

      Advanced Solid Tumor Trial (HEC169096)

      Not yet recruiting
      • Advanced Solid Tumor
      • (no location specified)
      Jul 6, 2022

      NSCLC Trial in Worldwide (Selpercatinib, Carboplatin, Cisplatin)

      Active, not recruiting
      • Non-Small Cell Lung Cancer
      • Berazategui, Buenos Aires, Argentina
      • +195 more
      Jan 30, 2023

      ALK-positive NSCLC (NSCLC), RET-positive NSCLC (NSCLC), RET-positive Thyroid Cancer Trial in Irvine, Boston (Alectinib)

      Terminated
      Has Results
      • ALK-positive Non-small Cell Lung Cancer (NSCLC)
      • +2 more
      • Irvine, California
      • +3 more
      Aug 30, 2021

      Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

      Not yet recruiting
      • Lung Cancer
      • Non Small Cell Lung Cancer
      • Amivantamab 1050mg
      • +2 more
      • Aurora, Colorado
      • +2 more
      Apr 25, 2023

      Advanced Nonhaematologic Malignancies Trial in Worldwide (BOS172738)

      Active, not recruiting
      • Advanced Nonhaematologic Malignancies
      • Philadelphia, Pennsylvania
      • +20 more
      Sep 23, 2022

      NSCLC, NSCLC Metastatic, NSCLC Recurrent Trial in Worldwide (Alectinib)

      Terminated
      • Non-small Cell Lung Cancer
      • +2 more
      • Brussels, Belgium
      • +18 more
      Aug 23, 2022

      Protein Kinase Inhibitors, Other Protocol Specified Criteria, Lung Tumors Trial in Guangzhou (JYP0322)

      Recruiting
      • Protein Kinase Inhibitors
      • +3 more
      • Guangzhou, Guangdong, China
        Sun Yat-Sen University Cancer Center
      Nov 9, 2023

      Patient Journey With Advanced Lung Cancer Positive for ALK

      Recruiting
      • Carcinoma, Non-Small-Cell Lung
        • Fortaleza, Ceará, Brazil
        • +4 more
        Sep 26, 2022

        Stage III NSCLC, Surgery Trial in Guangzhou (Lorlatinib)

        Not yet recruiting
        • Stage III NSCLC
        • Surgery
        • Guangzhou, Guangdong, China
          Guangdong Provincial People's Hospital
        Feb 21, 2023

        Non Small Cell Lung Cancer Trial in Seoul (Vandetanib)

        Completed
        • Non Small Cell Lung Cancer
        • Seoul, Korea, Republic of
        • +1 more
        Dec 4, 2020